https://scholars.lib.ntu.edu.tw/handle/123456789/637133
DC 欄位 | 值 | 語言 |
---|---|---|
dc.contributor.author | Chiu, Joanne Wing Yan | en_US |
dc.contributor.author | Lee, Soo Chin | en_US |
dc.contributor.author | Ho, James Chung-Man | en_US |
dc.contributor.author | Park, Yeon Hee | en_US |
dc.contributor.author | Chao, Ta-Chung | en_US |
dc.contributor.author | Kim, Sung-Bae | en_US |
dc.contributor.author | Lim, Elgene | en_US |
dc.contributor.author | CHING-HUNG LIN | en_US |
dc.contributor.author | Loi, Sherene | en_US |
dc.contributor.author | Low, Su Ying | en_US |
dc.contributor.author | Teo, Lynette Li San | en_US |
dc.contributor.author | Yeo, Winnie | en_US |
dc.contributor.author | Dent, Rebecca | en_US |
dc.date.accessioned | 2023-11-15T05:48:55Z | - |
dc.date.available | 2023-11-15T05:48:55Z | - |
dc.date.issued | 2023-10 | - |
dc.identifier.issn | 01145916 | - |
dc.identifier.uri | https://scholars.lib.ntu.edu.tw/handle/123456789/637133 | - |
dc.description.abstract | Trastuzumab deruxtecan (T-DXd)-an antibody-drug conjugate targeting the human epidermal growth factor receptor 2 (HER2)-improved outcomes of patients with HER2-positive and HER2-low metastatic breast cancer. Guidance on monitoring and managing T-DXd-related adverse events (AEs) is an emerging unmet need as translating clinical trial experience into real-world practice may be difficult due to practical and cultural considerations and differences in health care infrastructure. Thus, 13 experts including oncologists, pulmonologists and a radiologist from the Asia-Pacific region gathered to provide recommendations for T-DXd-related AE monitoring and management by using the latest evidence from the DESTINY-Breast trials, our own clinical trial experience and loco-regional health care considerations. While subgroup analysis of Asian (excluding Japanese) versus overall population in the DESTINY-Breast03 uncovered no major differences in the AE profile, we concluded that proactive monitoring and management are essential in maximising the benefits with T-DXd. As interstitial lung disease (ILD)/pneumonitis is a serious AE, patients should undergo regular computed tomography scans, but the frequency may have to account for the median time of ILD/pneumonitis onset and access. Trastuzumab deruxtecan appears to be a highly emetic regimen, and prophylaxis with serotonin receptor antagonists and dexamethasone (with or without neurokinin-1 receptor antagonist) should be considered. Health care professionals should be vigilant for treatable causes of fatigue, and patients should be encouraged to use support groups and practice low-intensity exercises. To increase treatment acceptance, patients should be made aware of alopecia risk prior to starting T-DXd. Detailed monitoring and management recommendations for T-DXd-related AEs are discussed further. | en_US |
dc.language.iso | en | en_US |
dc.relation.ispartof | Drug safety | en_US |
dc.title | Clinical Guidance on the Monitoring and Management of Trastuzumab Deruxtecan (T-DXd)-Related Adverse Events: Insights from an Asia-Pacific Multidisciplinary Panel | en_US |
dc.type | journal article | en |
dc.type | review | en_US |
dc.identifier.doi | 10.1007/s40264-023-01328-x | - |
dc.identifier.pmid | 37552439 | - |
dc.identifier.scopus | 2-s2.0-85167348180 | - |
dc.identifier.url | https://api.elsevier.com/content/abstract/scopus_id/85167348180 | - |
dc.relation.journalvolume | 46 | en_US |
dc.relation.journalissue | 10 | en_US |
dc.relation.pageend | 949 | en_US |
item.fulltext | no fulltext | - |
item.languageiso639-1 | en | - |
item.openairecristype | http://purl.org/coar/resource_type/c_6501 | - |
item.openairecristype | http://purl.org/coar/resource_type/c_18cf | - |
item.cerifentitytype | Publications | - |
item.cerifentitytype | Publications | - |
item.openairetype | journal article | - |
item.openairetype | review | - |
item.grantfulltext | none | - |
crisitem.author.dept | Internal Medicine | - |
crisitem.author.dept | Medical Oncology-NTUCC | - |
crisitem.author.dept | Oncology-NTUH | - |
crisitem.author.orcid | 0000-0003-2403-4056 | - |
crisitem.author.parentorg | College of Medicine | - |
crisitem.author.parentorg | National Taiwan University Cancer Center (NTUCC) | - |
crisitem.author.parentorg | National Taiwan University Hospital | - |
顯示於: | 醫學系 |
在 IR 系統中的文件,除了特別指名其著作權條款之外,均受到著作權保護,並且保留所有的權利。